Introduction and background
Chronic oedema is a debilitating, enduring condition connected with several chronic conditions, primary and secondary lymphoedema, obesity and immobility, with prevalence greatest within the older population (Todd 2013) . It is characterised by atypical swelling lasting for more than three months. Those affected may experience skin changes, recurrent cellulitis, superficial ulceration, exudate, lymphoedema and enduring pain, reduced mobility and discomfort (Todd 2013) . Evidence suggests that the impact of chronic oedema/leg ulcers on an individual's health, well-being, sense of self and quality of life may be profound and extends to all those who are important to the individual.
As a chronic debilitating condition, chronic oedema can have significant impact on health outcomes and result in a significant burden to the UK National Health Service (NHS).
Ineffective prevention and management alongside inappropriate prescribing of dressing and garments have been identified as significant issues and with appropriate management based on clinically and cost-effective technologies, the NHS could make substantial cost savings and enhance patient outcomes, including health-related quality of life (HRQOL) (Ashby et al, 2014) . Lymphoedema Network Wales have been developing innovative methods to support the management of chronic oedema within the community setting. One innovation has been the development of the OGEP which is a community-based education model involving the use of video prescription film applications as well as an educator training programme to support community health professionals and patients in the management and care of chronic oedema. The management includes daily activity and exercises, compression therapy/ multi layer lymphoedema bandaging, skin care and general public health promotion. Whilst the OGEP intervention requires additional investment in terms of resources to deliver, it could potentially result in more efficient use of health care resources including correct prescribing of dressing and garments from the All-Wales Lymphoedema Compression Garment Formulary (All-Wales Lymphoedema Compression Garment Formulary 2017), alongside improving outcomes and experiences for people living with chronic oedema.
Aim and objectives
The aim of this economic analysis, based on the pilot evaluation of the OGEP was to estimate the economic impact of the OGEP within one local University Health Board (UHB) within Wales. Specific objectives were to:  Assess the health care resource use and related costs associated with the delivery of the OGEP compared to 'no OGEP' i.e. the status quo.
 Estimate changes in the profile of health services delivered to patients as a result of the OGEP model.
 Provide a description of preference -based patient health outcome before and after receiving the OGEP.
The perspective taken was NHS/Personal Social Service (PSS) i.e. we considered direct health care costs across primary and secondary health care and direct costs associated with paid carers/social care (PSS).
Methods
The pilot evaluation design was an observational 'before-after design' with baseline assessment of resource use, costs and outcomes done at the time patients were identified and/or began to receive the OGEP and at 3 months afterwards. All patients were selected and recruited by the OGEP team, based on their eligibility to receive the OGEP during the pilot evaluation period. The estimated sample size within the evaluation period was 100 patients. As this was in effect a single arm study i.e. there was no comparator; the economic evaluation cannot fulfil the essential characteristic of a full economic evaluation in order to address questions of cost-effectiveness. Ethical approval was granted from Swansea University for data analysis on anonymised information. The UHB Research and Development department granted service evaluation approval.
Data collection measures
Data collection was administered by the OGEP team using an appropriate resource utilisation questionnaire (RUQ) to obtain health care resource use over a 3 months period.
The EQ-5D 5L (EUROQOL, 2017) was administered by the OGEP team at baseline and 3 months. The visual analogue scale (VAS) and descriptive system scores were also recorded by the OGEP team.
Resource use associated with the management and care of chronic oedema was summarized into relevant categories (e.g. primary care, secondary care, medication and dressing costs) and valued in £ sterling using a price year of 2016. The costs were determined from national published sources of unit costs [including All Wales Lymphoedema Compression Garment and Wound Care 2017), British National Formulary (BNF 2017), NHS reference costs (NHS 2016) and Personal and Social Services Research Unit (PSSRU 2016). Where costs were unavailable and/or the client wishes to use local costs (e.g. from local financial records or NHS Wales formulary). The currency year used was 2015/2016. If relevant costs were not available for these years, an inflation calculator (Bank of England) was used to convert costs to the price year(s).
Results
One hundred patients were recruited into the pilot evaluation by the OGEP team over the evaluation time period. Three participants died during the study prior to the 3 month followup assessment and were excluded from the analysis. The final sample included in the analysis was 97 participants. 64.9% of participants were female and 68% were from the Vale of Glamorgan. 32% were from the Cardiff North & West area with a mix of participants from the cluster of Barry 1 & 2, Cowbridge, Penarth, Rhiwbina and Whitchurch. Table 1 presents the overall costs of the OGEP intervention. This was estimated at £35,812 (£358.12 per patient) over the pilot evaluation period. The agreed intervention costs covered the staff resources associated with the delivery of the OGEP model of care. The biggest differences at baseline and follow up are seen in district nurse home visits (mean patient cost £1207.8; SD £976.9) vs. £565.8 (SD £563.3); a difference of -£641.9; 95% CI (-£478.5; -£805.4) at follow up. Other cost differences were seen in GP face-face and telephone visits, costs associated with length of hospital stay and hospital admissions for cellulitis. When costs of dressing are examined there is a difference of £337.7 (95% CI £154, £521.13) between before and after. As would be expected, there were numerical differences seen when comparing the mean and median costs; but overall the pattern of observed differences was similar.
Intervention costs
This indicates that health care costs are reduced, in key categories such as district nurse visits and dressing costs, reduction in length of hospital stay by an average of 47%, and 38% respectively when examined in the before and after comparison of the OGEP. Whilst the analysis provides no indication of whether such costs are as a direct result of OGEP (as no randomised comparator) or whether these costs differences are sustained or change over time; this snapshot provides a tentative indication where the potential for OGEP to be made in resource use and associated costs.
The costs were estimated, with a NHS perspective only (i.e. direct health care costs to NHS Wales) and Personal Social Services (PSS) presented alongside. Overall, the total costs were £563,729 at baseline and £445,098 (including the addition of intervention costs) at follow up; indicating a cost difference (reduction) of £118,631 in 97 patients. When a cost per patient was examined, this equated to a mean difference (cost reduction) of £1222.9 (95%CI -£344.5, -£2101.5) between follow up and baseline assessments. A similar numerical difference was seen when direct health care costs were examined separately. However, the confidence intervals are very wide thus caution should be applied in extrapolating these results to any definitive claim of 'cost saving or reduction'.
Patient HRQOL outcome
The results (Table 3) 
Summary
Overall, the results from the pilot intervention suggests an observed picture within a shortterm horizon of an overall cost reduction when direct health care and PSS costs are considered; with suggestion that resources (and associated costs) are shifted from key areas such as district nursing and dressings. Whilst the small numbers in secondary care resource and costs are limited; there may be areas where observed trends in cost reductions warrant further exploration. A small improvement in HRQOL score was observed in patients at 3 months compared to baseline.
Discussion
The analysis reported as part of the pilot evaluation has provided a first in-depth examination on the impact that the OGEP model could make in developing and rolling out best 'standard of care' practice in delivering chronic oedema management including promotion of daily exercises within the community. This evidence at grass roots level can provide, from the outset, important preliminary evidence as to where the OGEP could make differences to the management of chronic oedema within NHS Wales. Whilst from a decision makers' perspective this is often 'all about the evidence'; the pilot evaluation as a whole demonstrates that evidence should relate to the local health economy, patient health outcomes and experiences including the staff who are also beneficiaries of the OGEP through up-skilling their skills and competencies in delivering best standard care to this patient population. As Evidence of understanding where the potential cost drivers could be and whether health gains can be measured using instruments such as the EQ-5D 5L are fundamental components of pilot/feasibility work. A further, subsidiary research question from the analysis which may help future evaluations is formal examination of the validity, reliability and sensitivity of the EQ-5D 5L within this patient population. Whilst this was outside the scope of this current pilot evaluation period, further analysis of the data collected could yield important insights into the psychometric and clinical utility of using this preference-based generic health measure in patients with chronic oedema.
Limitations
From the outset, we have been mindful that some of the methodological and practical constraints have impacted on the strength of the evidence delivered by this evaluation. There is often a challenge in designing and conducting robust, 'academically grounded' evaluations when there is a compelling case for service innovation to respond quickly to meet unmet patient needs. Thus, the limitations often have to be set within context on what could be optimally achieved within real world settings.
Conclusion
The economic analysis has provided a first in-depth examination on the economic and patient impact that the OGEP could make in providing an innovative solution to delivering best standard of care practice. Whilst our findings suggest an observed trend for reductions in cost to NHS Wales; when disaggregated resource use and costs are examined, it also shows the possibility for a possible shift of health care resources across key areas of primary care
and secondary care. The promotion of proactive care proves beneficial over reactive care.
Further examination is required to assess whether these translate into potential efficiency gains (and important patient HRQOL gains) over the longer term. These findings can be used to inform the direction of any further development and evaluation of the OGEP model of care across NHS Wales.
